Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection.

[1]  C C Schulman,et al.  Prostate specific antigen density of the transition zone for early detection of prostate cancer. , 1998, The Journal of urology.

[2]  J. Holly.  Insulin-like growth factor-I and new opportunities for cancer prevention , 1998, The Lancet.

[3]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[4]  A. Partin,et al.  The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. , 1996, The Urologic clinics of North America.

[5]  W. Catalona,et al.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. , 1995, JAMA.

[6]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[7]  D. Peehl,et al.  The IGF axis in the prostate. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[8]  L. Giudice,et al.  Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. , 1992, The Journal of clinical endocrinology and metabolism.

[9]  C. Mantzoros,et al.  Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. , 1997, British Journal of Cancer.

[10]  P. Schellhammer,et al.  Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. , 1997, Urology.

[11]  P. Sluss,et al.  Insulin‐like growth factor I: Action and receptor characterization in human prostate cancer cell lines , 1993, The Prostate.